English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In recent decades, scientists have been attracted by the idea of developing methods for targeted transport of drugs and diagnostic drugs directly into the area of inflammation. Experimental and single clinical studies have revealed high efficiency and prospects for targeted delivery of various drugs. Most known carriers have a number of disadvantages, both in the range and amount of drugs they can bind, and in their ability to prevent contact of transport drugs with healthy tissues. In addition, there are difficulties associated with the toxicity and immunogenicity of carriers, their availability, cost, complexity of preparation. Transport systems that use the body's own cells are the most advantageous in terms of biocompatibility. Among them, erythrocytes, platelets and leukocytes are used as vehicles. Currently, the most promising in terms of drug transport is the use of erythrocyte containers. Pharmacokinetic studies have shown that with this route of administration, the concentration of antibiotic in the bile in patients with inflammatory diseases of the biliary tract, 4.7 times higher than with other routes of administration, and their therapeutic activity is maintained for a much longer time. When the erythrocyte containers were applied topically, the antibiotic concentration in the wound and surrounding tissue was 10 times higher than that achieved by traditional soft tissue puncture. In order to prove the ability of erythrocyte containers to capture drugs and concentrate in the inflammatory focus in 10 patients with this pathology at the beginning of treatment was injected into the femoral artery 1% 1 ml of nicotinic acid in 0.9% 2 ml of saline, and the following day the same patient in the same dose it was administered in erythrocyte containers. The time of onset of the reaction and the duration of the drug were determined, taking into account subjective and objective data. The ability of erythrocyte containers to seize drugs is evidenced by the results obtained by us: with the introduction of nicotinic acid in its pure form, the reaction occurred after 115411  0,0411and lasted 715211  0,0311. Objectively, there was a gradual reddening of the face and mild hyperemia. With the introduction of erythrocyte containers with nicotinic acid, the reaction occurred through 214311  0,0311 and lasted 1112411  0,0211. Subjectively, patients were characterized by a milder course of the reaction. The development of granulation tissue in the wound with the introduction of erythrocyte containers with antibiotics began on day 8-9, and the marginal epithelialization on day 10-12. In the control group, the appearance of granulation tissue and epithelialization in the wound were on 12-13 and 14-15 days, respectively.

USE OF ERYTHROCYTIC CONTAINERS FOR DELIVERY OF MEDICINES TO THE INFLAMMATION SITE